FDA Updates in Endocrinology
The end of the year brought many new FDA developments, including approval of a long-acting insulin and updated warnings for SGLT2 inhibitors.
Recent FDA news is outlined in the following slides.
FDA Updates in Endocrinology
Basaglar Wins FDA Approval - FDA alert.
FDA Eliminates REMS for Rosiglitazone-Containing Diabetes Medicines - FDA alert.
FDA Advisory Panel Against Expanded Indications for Ezetimibe - FDA alert. IMPROVE-IT trial.
FDA Updates of SGLT2 Inhibitors Labels - FDA alert.
FDA Approves Kanuma - FDA alert.
FDA Warns of Rare Cases of Underactive Thyroid in Infants - FDA alert.
